공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

쥐모델 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 850279
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


쥐모델 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 쥐모델의 시장 규모는 2021년부터 2026년까지 예측 기간 동안 6.8%의 CAGR를 기록할 것으로 예상됩니다.

현재 팬데믹 상황과 치료 및 백신 개발의 필요성에 따라, 쥐모델은 폭넓게 다양한 연구 기관과 바이오 의약품 산업의 비임상 시험에 사용되고 있습니다. 그러나 많은 국가가 락다운되어 무역을 중지하거나 여행 제한을 실시함에 따라 시장은 몰락했고, COVID-19 이외의 의약품 개발에 있어서 쥐모델을 사용하는 예는 크게 감소 했고, 시장 성장에 악영향을 끼치고있습니다. 공업 생산과 전임상 시험 감소 등 요인도 전세계 주요 기업의 시가 총액 감소에 이어지고 있습니다.

쥐모델 혁신 증가, 개별화 헬스케어 수요 증가, 제약 회사 및 바이오 의약품 기업의 파이프 라인 확대 등의 요인이 쥐모델 시장 성장을 뒷받침하고 있습니다. 인간 특이 적 감염, 치료 및 면역 반응의 연구에 대한 관심의 고조와 함께, 인간에 대한 약물의 효과를 평가하는 수요는 인간화 쥐모델의 개발과 사용에 이어지고 있습니다. 또한 대기업은 신규 출시에 따른 제품 포트폴리오의 확대에 주력하고 있습니다. 이처럼 제약 업계의 연구 개발 활동의 증가에 따라 쥐모델 시장은 확대되고 있습니다. 그러나 동물 실험과 동물의 윤리적 사용에 대한 규제는 시장 성장을 방해할 것으로 예상됩니다.

세계의 쥐모델(Mice Model) 시장을 조사했으며, 시장 개요/시장의 성장 요인 및 저해 요인 분석/시장 기회/유형별·지역별 시장 규모 추이 및 예측/경쟁 상황/주요 기업 개요 등 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장의 추진력
    • 혁신 증가
    • 개별화 헬스케어에 대한 수요
    • 제약 및 바이오 의약품 기업의 파이프 라인 성장
  • 시장의 억제 요인
    • 동물 실험 대안책
    • 동물의 윤리적 사용에 대한 규제
  • 포터의 5세력 모형

제5장 시장 세분화

  • 유형별
    • Inbred Mice
    • Outbred Mice
    • Genetically Engineered Mice
    • Hybrid/Congenic Mice
    • 기타
  • 서비스별
    • 번식
    • 동결 보존
    • 모델 인-라이센스(Model in-Licensing)
    • 유전자 검사
    • 기타 서비스
  • 기술별
    • CRISPR/CAS9
    • ES 세포 주입
    • 핵이식
    • 기타 기술
  • 애플리케이션별
    • 종양학
    • 심혈관
    • 신경
    • 기타 애플리케이션
  • 지역
    • 북미
    • 유럽
    • 아시아 태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Allentown, LLC
    • Charles River Laboratories International Inc.
    • ENVIGO
    • Genoway
    • Harbour Biomed
    • Horizon Discovery Group PLC(Sage Labs Inc.)
    • Ingenious Targeting Laboratory
    • Janvier Labs
    • Ozgene Pty Ltd.
    • PolyGene
    • Taconic Biosciences Inc.
    • The Andersons, Inc
    • The Jackson Laboratory
    • Trans Genic Inc.

제7장 시장 기회와 동향

LYJ 21.07.30

The global mice model market is expected to register a CAGR of 6.8% over the forecast period, 2021-2026.

Owing to the current pandemic situation and the urge to develop treatment and vaccine mice models have been extensively used in the pre-clinical development by various research laboratories and biopharmaceutical industries. According to an article published by the science advisory board in July 2020, researchers are using a strain of SARS-CoV-2 that can infect mice and further using it to produce a new mouse model of infection to help facilitate testing of COVID-19 vaccine candidates and therapies.

Although, there is a significant decline in the application of the mice model in drug development apart from COVID-19 because many countries had been in lockdown and have suspended the trades with other countries, implemented travel restrictions, etc., leading to declining in market capitalizations of major companies across the world, along with a decline in industrial production and pre-clinical trial which will negatively impact the market growth.

Factors such as increasing innovations in mice models, rising demand for personalized medicine, and growing pipeline of pharmaceutical and biopharmaceutical companies are driving the growth of the mice model market.

Mice models are one of the best small animal models for various infectious diseases including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Therefore these mice models are being widely used for several different viral investigations in pre-clinical researches.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), reported funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The growing demand to evaluate the effects of drugs on humans coupled with a rising focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized mice models.

In addition, Major companies are focusing on expanding their product portfolios by novel launches. In July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This novel model will save researchers months of planning and will accelerate the clinical development of NASH treatment for the treatment of liver failure.

Thus, the mice model market is expanding, with the increase in R&D activities in pharmaceutical industries. However, alternatives to animal testing and regulations for the ethical use of animals are the factors that are expected to be the restraint for the growth of the market.

Key Market Trends

Oncology Segment l is Expected to Hold the Significant Market Share Over the Forecast Period

By application by oncology, the segment is expected to hold a significant market share. The major factor propelling the growth of the segment is the rising burden of cancer coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development research. For instance, in August 2020, researchers in the meeting of the American Chemical Society reported that they are developing a new type of immunotherapy for triple-negative breast cancer. The researchers evaluated this therapy in mice models and concluded that it has dramatically extended the survival in triple-negative breast cancer in the mouse.

The Institute of Cancer Research, London stated that mice can be easily genetically altered to allow the study of the genetic causes of cancer and reproduce tumor types that naturally occur in humans for this they have been incorporating mice models in their pre-clinical trials for years. In 2017, 2018. And in 2019 ICR reported the use of 26,320, 23,525, and 25,771 mice in pre-clinical oncology testing. These mouse models are expected to revolutionize drug discovery research, such as the development and verification of various cancer therapies including cancer immunotherapy. Thus, the technological developments and funding by the major players to incorporate mice models in various stages of cancer treatment and diagnostic discoveries will boost the market growth.

North America is Expected to Dominate the Market Over the Forecast Period

Regionally, North America is expected to dominate the mice model market. The concentration of key players in the mice model market is the highest in the North American region. Additionally, the rising number of investments by the government for the development of innovations in mice models is spurring market growth.

For instance, The National Institute on Drug Abuse, United States has awarded an assistant professor at The Jackson Laboratory (JAX), an exploratory grant of USD 212,500, to identify genetic pathways involved in addiction behaviors using genome editing in mice models. Under the grant, the researchers will generate five new mice models with variation in Cyfip2 using CRISPR/Cas9 gene-editing technology.

In addition, market players are also focusing on market development strategies in order to increase their market share in the region. In April 2019, LabCorp and Envigo reported that LabCorp's Covance Drug Development segment will acquire Envigo's nonclinical research services business and Envigo's Research Models Services business will acquire the Covance Research Products business.

Also, in November 2019, Envigo announced an agreement to acquire the assets of the business unit of Horizon Discovery Group plc to combine Horizon transgenic model generation and contract breeding expertise with Envigo operational and commercial capabilities. This acquisition will boost the United State market with new products and services of mice models. All these developments are expected to increase the CAGR of the region during the forecasted period.

Competitive Landscape

The mice model market is made up of a network of players involved in research and product development, component manufacturing, distribution and sales, and post-sale services. The leading players in the market are offering services and CRISPR technologies as service models, which is experiencing an uptrend, due to increased drug development activity.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Innovation in Mice Models
    • 4.2.2 Rising Demand for Personalized Medicine
    • 4.2.3 Growing Pipeline of Pharmaceutical and Biophamraceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Alternatives to Animal Testing
    • 4.3.2 Regulations for the Ethical Use of Animals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Inbred Mice
    • 5.1.2 Outbred Mice
    • 5.1.3 Genetically Engineered Mice
    • 5.1.4 Hybrid/Congenic Mice
    • 5.1.5 Others
  • 5.2 By Service
    • 5.2.1 Breeding
    • 5.2.2 Cryopreservation
    • 5.2.3 Model in-Licensing
    • 5.2.4 Genetic Testing
    • 5.2.5 Other Services
  • 5.3 By Technology
    • 5.3.1 CRISPR/CAS9
    • 5.3.2 Embryonic Stem Cell Injection
    • 5.3.3 Nuclear Transfer
    • 5.3.4 Other Technologies
  • 5.4 By Application
    • 5.4.1 Oncology
    • 5.4.2 Cardiovascular Studies
    • 5.4.3 Neurology
    • 5.4.4 Other Applications
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allentown, LLC
    • 6.1.2 Charles River Laboratories International Inc.
    • 6.1.3 ENVIGO
    • 6.1.4 Genoway
    • 6.1.5 Harbour Biomed
    • 6.1.6 Horizon Discovery Group PLC (Sage Labs Inc.)
    • 6.1.7 Ingenious Targeting Laboratory
    • 6.1.8 Janvier Labs
    • 6.1.9 Ozgene Pty Ltd.
    • 6.1.10 PolyGene
    • 6.1.11 Taconic Biosciences Inc.
    • 6.1.12 The Andersons, Inc
    • 6.1.13 The Jackson Laboratory
    • 6.1.14 Trans Genic Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q